References
- American Cancer Society. Cancer Facts and Figures 2014. Atlanta, GA: American Cancer Society, 2014
- Larsen JE, Cascone T, Gerber DE, et al. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 2011;17:512-27
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
- Kelleher FC, McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer 2010;46:2357-68
- Li Y, Ye X, Liu J, et al. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 2011;13:1-11
- Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
- European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Xalkori. International non-proprietary name: crizotinib. Procedure No. EMEA/H/C/002489 [Internet]. [cited 2015 Mar 31]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002489/WC500134761.pdf
- Xalkori (crizotinib) capsules, oral [prescribing information]. New York, NY: Pfizer Labs, Division of Pfizer, 2013
- Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9
- Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71:6051-60
- Chun SG, Choe KS, Iyengar P, et al. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther 2012;13:1376-83
- Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-5
- Costa DB, Shaw AT, Ou S-HI, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015;33:1881-8
- Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97
- US Food and Drug Administration. Information for Healthcare Professionals (Drugs) – Accelerated Approval Program [Internet]. 2013 Jun [cited 2015 Mar 31]; Available from: http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm313768.htm
- Gridelli C, de Marinis F, Cappuzzo F, et al. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2014;15:173-81
- Fox KM, Brooks JM, Kim J. Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manag Care 2008;14:565-71
- Guerin A, Sasane M, Zhang J, et al. ALK-Translocation Testing and Treatment Patterns for Patients with ALK-Positive Non-small Cell Lung Cancer. Cancer Epidemiol 2015;39:307-12
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms and for defining comorbidities data in ICD-9-CM administrative. Med Care 2005;43:1130-9
- Zykadia approval letter [Internet]. 2014 [cited 2015 Mar 31]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755lbl.pdf
- Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28
- Ou S-HISHI, Jänne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014;25:415-22
- Costs were inflation-adjusted by a factor of 425.134/336.2 based on the average medical care CPI in 2006 and 2013, taken from the Archived Consumer Price Index Detailed Report Information [Internet]. [cited 2015 Feb 5]; Available from: http://data.bls.gov/cgi-bin/surveymost?cu
- Costs were inflation-adjusted by a factor of 110.667/102.330 based on the average Spanish health CPI in 2009 and 2013, taken from the Consumer Price Index, Base 2011, Annual Averages [Internet]. [cited 2015 Feb 5]; Available from: http://www.ine.es/dynt3/inebase/en/index.htm?padre=1967
- Euros were converted to US dollars based on the IRS 2013 yearly average currency exchange rate [Internet]. [cited 2015 Feb 5]; Available from: http://www.irs.gov/Individuals/International-Taxpayers/Yearly-Average-Currency-Exchange-Rates
- Isla D, González-Rojas N, Nieves D, et al. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol 2011;13:460-71
- Ramsey SD, Scoggins JF, Blough DK, et al. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm 2009;15:659-68
- Eichler AF, Lamont EB. Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol 2009;95:427-31